Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put, Sanofi (SNY - Free Report) stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, Sanofi has a trailing twelve months PE ratio of 15.77, as you can see in the chart below:
This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 compares in at about 20.83. If we focus on the stock’s long-term PE trend, the current level Sanofi puts current PE ratio above its midpoint (which is 13.65) over the past five years.
Also, the stock’s PE compares favorably with the Zacks Medical sector’s trailing twelve months PE ratio, which stands at 23.54. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.
We should also point out that Sanofi has a forward PE ratio (price relative to this year’s earnings) of 14.71, so it is fair to say that a slightly more value-oriented path may be ahead for the stock in the near term too.
Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.
Right now, the stock has a P/S ratio of about 2.97. This is a bit lower than the S&P 500 average, which comes in at 3.60 right now. Also, as we can see in the chart below, this is well below the highs for this stock in particular over the past few years.
If anything, this suggests some level of undervalued trading—at least compared to historical norms.
Broad Value Outlook
In aggregate, Sanofi currently has a Value Style Score of A, putting it into the top 20% of all stocks we cover from this look. This makes SNY a solid choice for value investors and some of its other metrics make it clear too.
For example, the PEG ratio for Sanofi is just 1.96, a level that is slightly lower than the industry average of 1.98. The PEG ratio is a modified PE ratio that takes into account the stock’s earnings growth rate. Additionally, its P/CF ratio (another great indicator of value) comes in at 9.81, which is far better than the industry average of 12.73. Clearly, SNY is a solid choice on the value front from multiple angles.
What About the Stock Overall?
Though Sanofi might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth grade of B and a Momentum score of F. This gives SNY a VGM score—or its overarching fundamental grade—of B. (You can read more about the Zacks Style Scores here >>).
Meanwhile, the company’s recent earnings estimates have been mixed. The current quarter has seen two estimates go lower in the past sixty days compared to none higher, while current year estimate has seen three upward and one downward revision in the same time period.
This has had a noticeable impact on the consensus estimate as the current quarter consensus estimate has declined 23.1% in the past two months, while current year estimate has inched up 0.9% in the same time period. You can see the consensus estimate trend and recent price action for the stock in the chart below:
This somewhat mixed trend is why the stock has just a Zacks Rank #3 (Hold) and why we are looking for in-line performance from the company in the near term.
Sanofi is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Moreover, a strong industry rank (Top 21% out of more than 250 industries) further supports the growth potential of the stock. In fact, over the past one year, the sector has clearly underperformed the broader market, as you can see below:
So, value investors might want to wait for estimates and analyst sentiment to turn favorable in this name first, but once that happen, this stock could be a compelling pick
More Stock News:
This Is Bigger than the iPhone! It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>